

Comments and illustrations of the WFUMB CEUS liver guidelines: Rare focal liver lesion – infectious parasitic, fungus

Tobias Zander¹, Ehsan Safai Zadeh², Kathleen Möller³, Christian Goerg², Jean Michel Correas⁴, Nitin Chaubal⁵, Klaus Dirks⁶, Alois Hollerweger⁷, Christian Jenssen^{8,9}, Christoph Klinger¹⁰, Adrian Lim¹¹, Yi Dong¹², Xin Wu Cui¹³, Nathally Espinosa Montagut¹⁴, David Srivastava¹⁵, Christoph F Dietrich¹

¹Department Allgemeine Innere Medizin, Kliniken Hirslanden, Beau Site, Salem und Permanence, Bern, Switzerland, ²Interdisciplinary Center of Ultrasound Diagnostics, University Hospital Giessen and Marburg, Philipps University Marburg, Germany, ³Medical Department I/Gastroenterology, SANA Hospital Lichtenberg, Berlin, Germany, ⁴Service de Radiologie Adultes, Hôpital Necker, Université Paris Descartes, Paris, France, ⁵Thane Ultrasound Centre, Jaslok Hospital and Research Department of Radiology and Center For Imaging Science, Centre, Mumbai, India, ⁶Rems-Murr-Klinikum, Winnenden, Germany, ⁷Department of Radiology and Nuclear Medicine, Barmherzige Brüder Hospital Salzburg, Austria, ⁸Department of Internal Medicine, Krankenhaus Märkisch Oderland GmbH, Strausberg/Wriezen, Germany, ⁹Brandenburg Institute for Clinical Ultrasound (BICUS) at Medical University Brandenburg „Theodor Fontane“, Neuruppin, Germany, ¹⁰Department of Internal Medicine 1, Klinikum Ludwigsburg, Ludwigsburg, Germany, ¹¹Imperial College London and Healthcare NHS Trust, London, UK, ¹²Department of Ultrasound, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China, ¹³Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹⁴School of Medicine, Universidad de los Andes, Bogotá, Colombia, ¹⁵Inselspital, University Hospital of Bern, Switzerland

Abstract

In this series of papers on comments and illustrations of the World Federation for Medicine and Biology (WFUMB) guidelines on contrast enhanced ultrasound (CEUS) the topics of parasitic and fungus infections are discussed. Improved detection and characterization of common focal liver lesions (FLL) are the main topics of these guidelines but detailed and illustrating information is missing. The focus in this paper on infectious (parasitic and fungus) focal liver lesions is on their appearance on B-mode and Doppler ultrasound and CEUS features. Knowledge of these data should help to raise awareness of these rarer findings, to think of these clinical pictures in the corresponding clinical situation, to interpret the ultrasound images correctly and thus to initiate the appropriate diagnostic and therapeutic steps in time.

Keywords: Liver lesions; candidiasis; parasitic diseases; ultrasonography; CEUS

Introduction

The World Federation for Ultrasound in Medicine and Biology (WFUMB) has published guidelines on the

use of contrast-enhanced ultrasound (CEUS) for the evaluation of focal liver lesions [1-5]. Improved detection and characterization of common focal liver lesions (FLL) are the main topics of these guidelines. In recent years, conventional ultrasound (US) and CEUS features of less common FLL and vascular have been described in detail [6-10]. In this current paper series, we aim to summarize the US and CEUS features of very rare FLL where there are limited reports and figures published in order to create a library of these rare lesions [10-19]. Parasites and fungal diseases have manifestations in the liver that pose a diagnostic challenge. Often they are incidental findings

Received 15.12.2022 Accepted 08.02.2023

Med Ultrason

2023;0 Online first, 1-12

Corresponding author: Prof. Dr. med. Christoph F. Dietrich, MBA
Department Allgemeine Innere Medizin (DAIM)
Kliniken Beau Site, Salem und Permanence,
Hirslanden, Bern, CH-3036 Bern, Schweiz
E-mail: c.f.dietrich@googlemail.com




Fig 1. A 23-year-old patient with a hypoechoic hepatic mass after aggressive chemotherapy for acute myeloid leukemia (A). On contrast-enhanced ultrasound, the lesion shows arterial rim hyperenhancement after 15 s (B) and after 20 s (C). After 1 min, the small central non-perfused area is unchanged. Clinically, a diagnosis of hepatic candidiasis was made. The FLL resolved after treatment.

or are detected in the context of unclear clinical scenario. Knowledge of such sonographic findings leads to an expansion of the differential diagnostic repertoire.

In various endemic regions of the world for parasitic diseases, liver lesions are part of the disease spectrum [20–26]. For some parasites, typical changes present themselves, on which a targeted diagnosis is based. For example, the diverse picture of liver lesions in echinococcus or the presentation of ascarids in the biliary system and the pancreatic duct.

It is important to evaluate the entity in the context of its occurrence. Pathogens in high-endemic areas of Africa and South-East Asia need to be known as well as infestations of immunocompromised individuals. This paper describes the sonomorphological changes and CEUS appearance of focal liver lesions in candidiasis, parasitic diseases in different endemic regions of the world or immune incompetent patients.

Hepatic candidiasis

In acute leukemia in the neutropenic patient, newly diagnosed hypoechoic liver lesions suggest candidiasis [27,28]. On CEUS, lesions that are similar on the B-scan can then be further differentiated. Mycotic abscesses can be differentiated from leukemic infiltrates, *Pneumocystis carinii* infections or hemophagocytosis syndrome manifestations. Hepatic candidiasis (HC) is seen in the course of chronic disseminated candidiasis [29]. It is most commonly observed in acute leukemia, at the stage of regeneration after therapy-induced neutropenia, with an incidence of 6.8% [30].

Imaging

The diagnosis is usually made clinically and on imaging, where B-mode US demonstrates multiple small-focal, <2 cm hypoechoic lesions in the liver and other solid organs [31]. However, the B-mode US appearance is non-specific and a definitive diagnosis can only be made

histologically, with evidence of granulomatous inflammation and evidence of fungi [29]. In clinical practice, this diagnostic confirmation is rarely performed, because patients usually have significant thrombocytopenia, and antifungal therapy is usually administered for the neutropenic sepsis [32]. As a result, biopsies are usually negative with respect to the detection of vital fungal organisms.

Basically, leukemic recurrences and other rarer syndromes, such as hemophagocytosis syndrome or *Pneumocystis carinii* infection, present identically on B-mode US [32]. Owing to the diagnostic uncertainty in these cases, CEUS plays an important role in patients with suspected HC allowing differentiation of these lesions from leukemic infiltrates and other disease entities by their enhancement characteristics [32]. A pathological/histological explanation for the variable ultrasound pattern remains undetermined [32]. It can only be speculated that the presence of a margin of hyperenhancement is indicative of florid inflammation. Another CEUS characteristic is the obligatory detection of a non-perfused central area of variable size (fig 1).

Hepatic alveolar echinococcosis

Alveolar echinococcosis (AE) is a rare chronic zoonosis caused by the larval stage of *Echinococcus multilocularis*, a cestode parasite. In humans, the disease typically presents with liver involvement. Extrahepatic manifestations are rare (13% of cases affect the lung, spleen, or brain). Patients complain of unspecific symptoms such as right upper quadrant discomfort (hepatomegaly), weight loss, or malaise. Infrequent manifestations include obstructive jaundice, cholangitis, and portal hypertension due to vascular invasion (portal or hepatic veins). Although AE is a non-neoplastic disease, the inflammatory tissue growth induced by the parasite resembles that of slow-growing malignant tumors, progressively exhibiting infiltrative growth, invasion of adjacent organs and vessels, and distal metastasis [33]. If left untreated, the

prognosis of the disease after the onset of symptoms is poor, with a mortality rate of over 90% at 10 years [34]. Therapy options dramatically improve the prognosis and include (curative) surgery and benzimidazoles (e.g., Albendazole, Mebendazole). The diagnosis is usually made via imaging in combination with serology.

Imaging

On US, AE lesions can be indistinguishable from malignancy (particularly cholangiocarcinoma and hepatocellular carcinoma), especially since the vessels can be invaded. Notably however, the general conditions of patients with AE are usually much better than those with malignancy. The described US imaging features of AE are either of a hyperechogenic (around 50% of published cases), hypoechogenic, or heterogeneous solid lesion with irregular and poorly defined margins. Small calcifications in the periphery have been described in 50–70% of the cases, and this can help with the diagnosis. The size of the lesions varies from several centimeters to involving most of the liver, often the right liver (fig 2, fig 3). The following imaging classification system describes five types of sonographic changes in hepatic alveolar echinococcus [35] (fig 4).

- Type 1: A hailstorm pattern appearing as heterogeneously echogenic areas with irregular contours and visibly scattered hyperechoic areas; calcifications can be observed in some cases.
- Type 2: A pseudocystic pattern with an irregular hyperechoic rim that is not vascularized on power Doppler and CEUS imaging.
- Type 3: A metastasis-like pattern.
- Type 4: A hemangioma-like pattern.
- Type 5: An ossification pattern with calcification features.

In a separate study, the most frequent patterns of AE lesions in the liver were the hailstorm and pseudocystic patterns. There was no correlation between the clinical stage of the disease and the US appearance of the lesions [36]. Few studies have evaluated the CEUS behavior of AE [37-41]. Research using first-generation ultrasound contrast agent (UCA) (Levovist) have suggested an absence of enhancement in AE [42]. However, more recent data with second-generation UCAs have revealed that enhancement is frequent (78% in the most recent series). A recent study indicates several changes with CEUS: 23 lesions (53.5%, or 23 out of 43) display no enhancement




Fig 2. Hepatic Alveolar Echinococcosis (HAE): A – a large heterogenous lesion (about 12 cm) with solid aspect is visualized in the right liver in B-mode ultrasound. Note the small hyperechoic spots that correspond to microcalcification. B – the lesion infiltrates the right posterior branch of the portal vein, which has a truncated aspect (arrow); C and D - another example of a very large hepatic alveolar Echinococcosis. Note again the solid aspect, in this case mostly hyperechoic; at the periphery of the lesion very small hyperechoic spots corresponding to microcalcifications are visualized. Also in this case, there is infiltration of the portal vein.




Fig 3. A 49-year-old patient with hypointense hilar liver lesion on computed tomography (courtesy of Prof. Dr. Mahnken, Department of Radiology, University Hospital Marburg) (A) and B-mode ultrasound (B). On contrast-enhanced ultrasound, the lesion showed an absence of enhancement after 20 s (C) and 1 min (D). Histologically and serologically, the diagnosis of alveolar echinococcosis was confirmed.




Fig 4. A 67-year-old patient with serologically confirmed cystic echinococcosis and with corresponding patterns of liver involvement on B-mode and contrast-enhanced-ultrasound: (A) type I (pure cyst); (B) type II (cyst within cyst); (C) type III (water lily sign); (D) type IV (solid impinging); and (E) type V (calcifications).

in the arterial, portal, and delayed phases with CEUS imaging. Meanwhile, 11 lesions (25.6%, 11/43) display a slight rim-like hyperenhancement in the arterial phase and hypoenhancement in the portal and delayed phases, and 6 lesions (14%, 6/43) display hyperenhancement in the arterial phase and hypoenhancement in the portal and delayed phases. Two lesions (4.7%, 2/43) exhibit iso-enhancement in the arterial, portal, and delayed phases, whereas one (2.3%, 1/43) showed slight hypoenhancement in the arterial, portal, and delayed phases [43]. From a structural point, the most common aspect is circular rim (i.e., peripheral) enhancement, with a lack of central enhancement, and this has been described in about one-third of the published lesions. Early arterial enhancement is seen in some patients (circa 30%), while enhancement in the portal venous phase only was observed in the remaining cases.

The correlation between pathological and CEUS findings remains controversial. Based on one study performed with an animal model [44], larger lesions may have more pronounced peripheral and central enhancement due to the development of small neoangiogenic vessels in the inflammatory tissue surrounding the parasitic vesicles. Whether contrast enhancement corresponds to more active lesions has not been fully elucidated. In one study [40], CEUS using SonoVue[®] was compared to three-phase helical CT and positron-emission tomography with ¹⁸F fluorodeoxyglucose (FDG-PET). Lesions with enhancement on CEUS are also metabolically active on FDG-PET, suggesting that CEUS could be useful in this regard. However, FDG-PET reveals significantly

more active lesions than CEUS, and more data is needed before recommending its routine use in patients on drug therapy. Previously, CT was considered the method of choice [45]. In CT scans, lesions are most often hypodense (70% of cases), and calcifications have been identified with higher sensitivity using this technique than via US. Disease activity, meanwhile, is better studied using FDG-PET. Since hydatid cysts have been recently summarized in detail by the authors, they have not been included as part of this paper [22,23,25].

Fascioliasis

Fascioliasis is a zoonotic disease caused by two main liver fluke species of the *Fasciola* genus: *Fasciola hepatica* and *Fasciola gigantica* [46]. Fascioliasis is typically a rural distomatosis that commonly affects livestock such as sheep, goats, buffaloes, and cattle; humans are accidental hosts of the parasite [47]. The most common symptoms are abdominal pain, weight loss, and fever. One study suggests that the mean duration starting from the onset of symptoms to a definite diagnosis is 44.3 ± 39.1 days. In physical examinations, the most common clinical signs are tenderness in the epigastrium or the right side of the abdomen, followed by hepatomegaly and fever. Jaundice is relatively uncommon in this condition [48]. The treatment of choice for fascioliasis in humans is a single oral dose of 10 mg/kg triclabendazole.

Imaging

US findings are nonspecific (fig 5-7) and include focal hypoechoic or hyperechoic lesions or diffuse in-




Fig 5. Fasciolosis hepatica (serological proven) in a 19-year-old woman with abdominal feeling of pressure and eosinophilia of 30%. The grey scale ultrasound displays confluent hypoechoic lesions up to 4 cm in the right liver lobe, which were blurred and without a halo (A). In the porta hepatis, enlarged and rounded lymph nodes up to 2.2 cm were detected (B) CEUS demonstrates arterial contrast enhancement in the outer areas (C) and increasing washout in the late phase (3:49 minutes, D).




Fig 6. Fasciolosis (serological and histological proven). 76 y/o female from Eastern Turkey presenting with subfebrile temperature, weight loss and eosinophilia. B-mode ultrasound showed a heterogeneous lesion in liver segment VI (A). Contrast enhanced ultrasound CEUS revealed a rim-like peripheral enhancement during the arterial phase (B) with slight washout during the delayed phase (C) and confluent unenhanced central areas correlating to the eosinophilic abscess caused by the fluke's migration (D).

involvement of the liver. CEUS reveals rim-like peripheral enhancement during the arterial phase, with a slight washout during the portal venous and delayed phases. Most striking are the confluent unenhanced central areas associated with the eosinophilic abscess and the migration route of the fluke [21,49]. It is worth noting that due to scar tissue, unenhanced areas may persist for years after successful treatment. An abdominal CT scan demonstrates a conglomerated hypodense lesion (89%), rim-enhanced lesion (71.4%), subcapsular or peripheral location (72.3%), and tubular branching track described as a serpiginous track resulting from parasitic migration

(64.6%). Other findings include single hypodense lesions (10.9%), cystic lesions (8%), centrally located lesions (14.3%), scattered lesions in both lobes (10.6%), and localized perihepatic fluid accumulation (10.3%). Portal vein thrombosis was observed in 17 patients (9.7%). The associated extrahepatic findings include intra-abdominal lymph node enlargement (40.6%), ascites (13.7%), and presence of an abdominal wall abscess (4%). Bile duct dilatation was found in 40 patients (22.9%) [48].

Clonorchis and opisthorchis

The liver fluke *Clonorchis sinensis* is a high-risk, pathogenic parasitic helminth that is endemic to and actively transmitted predominantly in Asian countries, including Korea, China, Taiwan, Vietnam, and the far eastern parts of Russia. Clonorchiasis and opisthorchiasis are characterized by chronic infection that induces hepatobiliary inflammation, especially periductal fibrosis, which can be detected by US. To reduce hepatobiliary morbidity, the primary intervention measures focus on control and elimination of the liver fluke [50]. The short-term goal of liver fluke control can be achieved by praziquantel chemotherapy. US reveals various findings,




Fig 7. Fasciolosis (serological proven). Abscess formation can be proven only by CEUS (a, b).

most commonly small- and medium-sized intrahepatic bile duct narrowing, with subsequent pre-stenotic bile duct dilatation. Depending on the stage of the disease, hypoechoic periductal edema or hyperechoic periductal fibrosis may be found [26]. Furthermore, fluke aggregates may be detected as hyperechoic spots within the bile ducts. Over the time, such aggregates may cause hypo- to isoechoic nodules, which coalesce and lead to heterogeneous echogenicity of the liver.

Ascariasis of the liver

Ascariasis is a common cause of hepatic abscesses in certain regions of the world. Imaging sometimes reveals pathognomonic features such as the typical morphology of an adult worm in the diagnosis of hepatic ascariasis. However, it is not sensitive, and most infections do not manifest such characteristic features. This means that a lack of imaging abnormalities does not confirm the absence of ascariasis. Moreover, the infection can be easily diagnosed through a parasitological stool examination. Imaging is therefore indicated only when diagnosis is difficult or if complications are suspected [51].

Fine-needle aspiration cytology from the liver abscess could display an ascariasis-associated result. Patients with hepatic abscesses develop pain in the right hypochondrium, high fever, point tenderness in the first intercostal space, and edema of the right lateral chest wall [52]. Ascarides are localized in the intrahepatic ducts in most of these patients. Pus from the abscess often indicates *Ascaris* ova and/or fragments of dead ascarides [53]. In US images, hepatic ascariasis may contain single or multiple long, linear or curved echogenic structures without acoustic shadowing. A long, thick linear or curved non-shadowing echogenic strip containing a central longitudinal anechoic tube (i.e., a 4-line sign) represents the digestive tract of the worm [51]. While gallbladder ascariasis (GB) has been abundantly described in the literature, this is a relatively rare manifestation constituting only 2.1% of all hepatobiliary manifestations. Its characteristics are writhing movements of the echogenic strips within the ducts. Other signs include gallbladder and cystic duct distension, gallbladder wall edema, sludge within the gallbladder, and multiple liver abscesses [53]. Retained worm fragments can serve as a nidus for biliary stones. Other rare conditions such as microgallbladder in cystic fibrosis have to be ruled out (34). Compared to B-mode US, CEUS can be used to differentiate between GB tumors and GB ascariasis debris with a higher degree of confidence [54]. Furthermore, GB ascariasis debris may present with solid solitary hyperechoic lesions in the gallbladder in conventional B-Mode

US with no mobility in the standing position. Zigzag and multiple parallel echogenic lines were detected in the lumen of the gallbladder. After an injection of 2.4 ml US SonoVue, no enhancement could be observed throughout the entire enhancement period (non-published data).

Schistosomiasis

Schistosomiasis remains a public health problem in many parts of the world, particularly in Africa, where 93% of the total population require chemotherapy to prevent the complications of the disease, namely hepatic fibrosis and portal hypertension, urinary tract obstruction, hydronephrosis and bladder cancer, as well as sequelae involving the reproductive tract [55]. Since eradication of schistosomiasis is difficult, the WHO has focused on morbidity control. Consequently, morbidity assessments are crucial. Ultrasound is a pivotal method to assess the morbidity due to schistosomiasis and its complications in endemic countries [47,56-58]. In general, US examination of patients with schistosomiasis should refer to the WHO Niamey-Belo Horizonte protocol so that the data can be compared on an international scale. Although estimates are not available, schistosomiasis must be considered to be the most frequent cause of liver fibrosis worldwide [59].

The typical US features of schistosomal Symmers' fibrosis include echogenic bands, streaks, and areas accompanying portal branches compared to standard images [60,61]. Portal fibrosis may be graded by comparing the liver sonomorphology with standard imaging patterns. Furthermore, *S. japonicum* may cause portal fibrosis and/or interseptal hepatic fibrosis, which by imaging techniques resemble "network-" or "tortoise-back"-like liver aspects [57,58,62]. Portal hypertension is indicated by portal vein dilatation. Doppler US may be misleading in cases where the flow is not reduced and can even be increased from the enlarged spleen to the liver. In well-equipped hospitals, endosonography, CT, and especially MRI may contribute to further assessment of liver fibrosis and the associated hemodynamic abnormalities [63]. Gallbladder abnormalities usually occur in patients with advanced hepatic portal fibrosis due to a *Schistosoma mansoni* infection. Gallbladder abnormalities have occasionally been observed in children, and they may occur without associated overt liver abnormalities. The specific *S. mansoni*-induced gallbladder abnormalities detectable by US include typical hyperechoic wall thickening with external gallbladder wall protuberances whereby the luminal wall surface is smooth [64].

Toxocariasis

Toxocariasis is caused by ascarids in dogs known as *Toxocara canis*; it leads to eosinophilic inflammation such as eosinophilic abscesses or granuloma in the liver and lungs. Due to the slow movement of the lesions, the disease is known as visceral larva migrans. In CT or MR imaging, hepatic lesions are observed as multiple ill-defined oval lesions that measure 1.0–1.5 cm in diameter [65]. Sometimes, they may be angular or trapezoidal. The lesions are usually best seen in the portal venous phase via dynamic contrast-enhanced CT and MR imaging. They are either invisible or only faintly visible in the arterial and equilibrium phases; either with an enhancing rim or occasionally enhancing nodules can be observed. Sonographically, the lesions appear as multiple small, oval hypoechoic lesions in the liver parenchyma. They differ from metastatic nodules in that they have fuzzy margins, are uniform in size and non-spherical, and are best observed during the portal venous phase. In follow-up images, the lesions may improve or sometimes change positions, reflecting migration of larva in the liver, supporting the phenomenon of visceral larva migrans [66].

Paragonimus

Paragonimiasis is a parasitic lung infection caused by lung flukes of the *Paragonimus* genus, with most cases reported in East Asia and caused by *P. westermani* following the consumption of raw or undercooked crustaceans. Ectopic infection may occur and most commonly involves the brain and striated muscle. Involvement of the liver is rare with only case reports and no larger studies reporting liver involvement [67]. Drug therapy such as praziquantel is the first choice for hepatic paragonimiasis.

Imaging

Hepatic Paragonimus (HP) lesions are often incidentally detected on routine US. Typically, HP presents as subcapsular hyperechoic lesions with irregular, tract-like, non-enhancing areas of necrosis on CEUS [68]. Liver biopsy is usually performed for diagnosis distinguish it from other liver lesions [69]. In addition to more invasive methods, US, CT, and serum laboratory studies can be used to establish the diagnosis of HP. Abdominal CT reveals multiple low-density lesions (poorly circumscribed with inhomogeneous enhancement, suggestive of areas of necrosis), formation of visible partitions, and absent invasion of adjacent vessels [70]. The presentation of Paragonimus in MRI may mimic hepatocellular carcinoma with a mass of inhomogeneous signal intensity. The lesion may exhibit mild enhancement and restricted diffusion [71].

Lepra

Leprosy is a systemic infectious disease affecting several parenchymal organs to varying extents. Next to the neurocutaneous system, the liver is the most common organ involved. Hepatic granulomas have been reported predominantly in patients with lepromatous leprosy and are rare in those with tuberculoid leprosy. Abnormal US findings include an inhomogeneous echo texture of the hepatic parenchyma in all cases [72]. However, hepatic sonography was conducted on 36 patients with lepromatous leprosy and 3 with borderline lepromatous leprosy. No definite abnormal sonographic findings were observed in the liver for a large majority of these patients [73].

Primary toxoplasmosis of the liver

Hepatic toxoplasmosis is associated with elevated serum alkaline phosphatase activity and minimally elevated lactate dehydrogenase levels [74]. Liver pathologies and infection with *Toxoplasma gondii* are widespread among HIV-infected patients. Among these patients, *T. gondii* is a weak, nonspecific adjunct that supports chronic liver inflammation and the progression to cirrhosis, but it does not influence the degree of hepatitis activity regardless of the etiology.

Focal pneumocystis carinii

Pneumocystis carinii is a frequent cause of interstitial pneumonitis in patients with cell-mediated immunodeficiencies. Extrapulmonary *P. carinii* infection is a rare manifestation of disease caused by this organism. Nevertheless, reports of such infections are increasing in the setting of the acquired immunodeficiency syndrome (AIDS; [75]. *Pneumocystis carinii* pneumonia (PCP) is an opportunistic infection associated with morbidity and mortality in solid-organ transplant recipients [76].

Leishmaniasis

Leishmaniasis is a global infectious disease with obligatory intracellular protozoan parasites of the *Leishmania* genus. It is endemic in East Africa, Latin America, and Southeast Asia, areas in which malnutrition is associated with high concentrations of the parasite. However, foci of infection have also been found in the Mediterranean and the Middle East. The transmission takes place through the sand mosquito (genus *Phlebotomus*). Leishmaniasis has three manifestations: cutaneous, mucocutaneous, and visceral. Liver involvement is present in

the visceral form. Approximately 500,000 new cases of leishmaniasis occur each year, and an estimated 50,000 to 90,000 new cases of visceral leishmaniasis (VL) occur worldwide annually, of which only between 25 to 45% are reported to the World Health Organization (WHO; [77]). The pathogens of the disease take the form of *L. donovani* worldwide and *L. infantum* in Europe [78]. The most common symptoms and clinical signs are weight loss, fever, loss of appetite, hepatosplenomegaly, pancytopenia, and lymphadenopathy [79-81]. In the case of HIV infection, the risk of contracting leishmaniasis is increased significantly [82]. Visceral leishmaniasis is often atypical and fulminant in immunosuppressed patients [83]. The protozoa invade macrophages, which are found in the bone marrow, liver, spleen, and lymph nodes [84-86]. If visceral leishmaniasis is clinically suspected, microscopic detection of the pathogen in bone marrow is the method of choice. The pathogen can be directly detected through biopsy of the infected tissue, which is conducted by examining the bone marrow needle aspirates or from other affected organs with evidence of *Leishmania* amastigotes [79,84,87-89]. Alternatively, PCR from peripheral blood or serological diagnostics can be used [83]. The infection induces granulomatous inflammation [87,90-92], and therapy for visceral leishmaniasis is always systemic. Liposomal amphotericin B is the drug of first choice [83,93].

Imaging

Hepatosplenomegaly is a very common and detectable sonographic change in visceral leishmaniasis. In addition to observations of lymphadenopathy, small hypoechoic lesions are often detected in the spleen [78, 79,81,94-100]. Focal liver lesions are extremely rare [101]. Bükte et al report a case of visceral leishmaniasis with such lesions [97]. The liver was markedly enlarged, with heterogeneous, partly smooth-edged peripheral hypoechoic haloes of isoechoic or slightly hypoechoic structure, the largest of which measured 61x50 mm and contained multiple solid nodular lesions with hypoechoic necrotic regions. Microscopically, numerous intramacrophage *Leishmania* amastigotes were detected in the aspirate from the liver lesions. The authors considered the liver lesions to be abscesses [97].

Vascular changes in the liver have not been reported in visceral leishmaniasis. Since granulomatous inflammation has been histologically described in the liver in this disease, it is conceivable that imaging would find focal (granulomatous) lesions. However, such lesions have not been reported in the literature. A recent review of previous research regarding sonographic findings in visceral leishmaniasis includes 36 publications with 512 patients [102]. Among these, few publications report on

focal liver lesions with a heterogeneous echopattern. As sonographic findings tend to resolve within several days to weeks after successful treatment, ultrasound can be a valuable, non-invasive tool for treatment monitoring. To the best of our knowledge, there have been no publications to date regarding the use of CEUS in the diagnostic work-up or the follow-up of visceral leishmaniasis.

Conclusion

If focal liver lesions are detected, parasitic and, especially in immunocompromised patients, fungal diseases must be considered in the clinical context. New singular or multiple hypoechoic parenchymal lesions in patients with acute leukemia and neutropenia are highly suggestive of mycotic abscesses. In endemic areas of certain parasitic diseases again, these must be included in the differential diagnostic considerations from the beginning. This can also affect traveler returning from these areas. The manifestations on B-mode ultrasound are diverse. Parasitic liver lesions may be hypoechoic or hyperechoic lesions, complex solid or cystic lesions, well circumscribed lesions or infiltrative processes. The changes may be very bizarre in appearance, calcifications may be present. The parasitic diseases cannot be diagnosed from the sonomorphological B-scan alone. A disease such as hepatic alveolar echinococcus may manifest with multiple different appearances of focal lesions. CEUS may be helpful in parasitic abscesses to show inflammatory hyperemia of the surrounding area and non-perfused central areas. A contrast-enhancing rim has been described for quite a few echinococcal lesions. Important differential diagnoses of parasitic liver lesions are bacterial abscesses and tumors. Differentiation from tumors can be difficult in individual cases, as eosinophilic infiltrates or granulomatous changes also present as non-liver tissue on CEUS. Hepatobiliary complications caused by clonorchiasis and opisthorchiasis, such as strictures and cholangitis, can be visualised and, depending on the progression, show periductal changes as well as echogenic intraductal changes of the flukes themselves. Ascariasis can affect the entire hepatobiliary system and pancreas. The ascarids can be identified sonographically.

In the case of sonographic periportal changes, parasitic infections should be evaluated if there is a geographical prevalence of schistosomiasis. It is always important to see the lesions in the overall context. In appropriate regions of the world, parasitic diseases must be included in the differential diagnostic considerations and appropriate serological tests and stool examinations must be arranged.

Conflict of interest: none

References

1. Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform Contrast-Enhanced Ultrasound (CEUS). *Ultrasound Int Open* 2018;4:E2-E15.
2. Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. *Ultraschall Med* 2013;34:11-29.
3. Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. *Ultrasound Med Biol* 2013;39:187-210.
4. Dietrich CF, Nolsoe CP, Barr RG, et al. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. *Ultrasound Med Biol* 2020;46:2579-2604.
5. Dietrich CF, Nolsoe CP, Barr RG, et al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. *Ultraschall Med* 2020;41:562-585.
6. Moller K, Braden B, Culver EL, et al. Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis - A review of cholangiographic and ultrasound imaging. *Endosc Ultrasound* 2022.
7. Möller K, Tschu T, De Molo C, et al. Comments and illustrations of the WFUMB CEUS liver guidelines: rare congenital vascular pathology. *Med Ultrason* 2022;24:461-472.
8. Moller K, Safai Zadeh E, Gorg C, et al. Prevalence of benign focal liver lesions and non-hepatocellular carcinoma malignant lesions in liver cirrhosis. *Z Gastroenterol* 2022, doi: 10.1055/a-1890-5818.
9. Ignee A, Moeller K, Thees-Laurenz R, et al. Comments and illustrations of the WFUMB CEUS liver guidelines: Rare focal liver lesions - infectious, bacterial. *Med Ultrason* 2023, doi: 10.11152/mu-4065.
10. Moller K, Zadeh ES, Görg C, et al. Comments and illustrations of the WFUMB CEUS liver guidelines: Rare vascular pathology, part II. *Med Ultrason* 2022, doi: 10.11152/mu-4013
11. Dong Y, Wang WP, Lee WJ, et al. Contrast-Enhanced Ultrasound Features of Histopathologically Proven Hepatocellular Carcinoma in the Non-cirrhotic Liver: A Multicenter Study. *Ultrasound Med Biol* 2022;48:1797-1805.
12. Dong Y, Braden B, Klinger C, Ripolles T, Dietrich CF. Ultrasound findings in extragenital endometriosis. *J Ultrason* 2018;18:247-254.
13. Dong Y, Koch J, Alhyari A, et al. Ultrasound Elastography for Characterization of Focal Liver Lesions. *Z Gastroenterol* 2022, doi: 10.1055/a-1957-7370.
14. Dong Y, Koch JBH, Lowe AL, et al. VueBox(R) for quantitative analysis of contrast-enhanced ultrasound in liver tumors. *Clin Hemorheol Microcirc* 2022;80:473-486.
15. Dong Y, Teufel A, Trojan J, Berzigotti A, Cui XW, Dietrich CF. Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature. *Dig Liver Dis* 2018;50:401-407.
16. Dong Y, Teufel A, Wang WP, Dietrich CF. Current Opinion about Hepatocellular Carcinoma <10 mm. *Digestion* 2020:1-7.
17. Dong Y, Wang WP, Lee WJ, et al. Hepatocellular carcinoma in the non-cirrhotic liver. *Clin Hemorheol Microcirc* 2022;80:423-436.
18. Dong Y, Wang WP, Lim A, et al. Ultrasound findings in peliosis hepatis. *Ultrasonography* 2021;40:546-554.
19. Moeller K, Safai Zadeh E, Goerg C, et al. Focal liver lesions other than hepatocellular carcinoma in cirrhosis: Diagnostic challenges. *J Transl Int Med* 2022;10:308-327.
20. Dietrich CF, Chaubal N, Hoerauf A, et al. Review of Dancing Parasites in Lymphatic Filariasis. *Ultrasound Int Open* 2019;5:E65-E74.
21. Dietrich CF, Kabaalioglu A, Brunetti E, Richter J. Fasciolosis. *Z Gastroenterol* 2015;53:285-290.
22. Dietrich CF, Douira-Khomsi W, Gharbi H, et al. Cystic echinococcosis, review and illustration of non-hepatic manifestations. *Med Ultrason* 2020;22:319-324.
23. Dietrich CF, Douira-Khomsi W, Gharbi H, et al. Cystic and alveolar echinococcosis of the hepatobiliary tract - the role of new imaging techniques for improved diagnosis. *Med Ultrason* 2020;22:75-84.
24. Dietrich CF, Cretu CM, Atkinson NSS, et al. Imaging of toxocarosis. *Z Gastroenterol* 2019;57:327-334.
25. Brunetti E, Tamarozzi F, Macpherson C, et al. Ultrasound and Cystic Echinococcosis. *Ultrasound Int Open* 2018;4:E70-E78.
26. Dietrich CF, Atkinson NSS, Lee WJ, et al. Never seen before? Opisthorchiasis and Clonorchiasis. *Z Gastroenterol* 2018;56:1513-1520.
27. Trenker C, Kumpel J, Michel C, Sa et al. Assessment of Early Therapy Response of Non-Hodgkin's and Hodgkin's Lymphoma Using B-Mode Ultrasound and Dynamic Contrast-Enhanced Ultrasound. *J Ultrasound Med* 2022;41:2033-2040.
28. Trenker C, Gorg C, Jenssen C, Klein S, Neubauer A, Dietrich CF. [The role of abdominal ultrasound in hematological diseases]. *Z Gastroenterol* 2018;56:1063-1076.
29. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. *Ann Intern Med* 1988;108:88-100.
30. Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. *Clin Infect Dis* 1997;24:375-380.
31. Görg C, Weide R, Schwerk WB, Köppler H, Havemann K. Ultrasound evaluation of hepatic and splenic microabscesses in the immunocompromised patient: sonographic

- patterns, differential diagnosis, and follow-up. *J Clin Ultrasound* 1994;22:525-529.
32. Görg C, Bert T, Klassen E, Neesse A, Barth P, Neubauer A. Kontrastunterstützte sonografische Befunde bei hepatischer Candidiasis. *Zeitschrift für Gastroenterologie* 2010;48:678-682.
 33. Li H, Song T, Shao Y, Wen H. Cystic echinococcosis accompanied by hepatocellular carcinoma in a female herdsman. *Int J Clin Exp Med* 2015;8:2985-2988.
 34. Ammann RW, Eckert J. Cestodes. Echinococcus. *Gastroenterol Clin North Am* 1996;25:655-689.
 35. Kratzer W, Gruener B, Kaltenbach TE, Ansari-Bitzenberger S, Kern P, Fuchs M, Mason RA, et al. Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcosis multilocularis Ulm classification-ultrasound. *World J Gastroenterol* 2015;21:12392-12402.
 36. Sulima M, Nahorski W, Gorycki T, et al. Ultrasound images in hepatic alveolar echinococcosis and clinical stage of the disease. *Adv Med Sci* 2019;64:324-330.
 37. Liu W, Delabrousse E, Blagosklonov O, et al. Innovation in hepatic alveolar echinococcosis imaging: best use of old tools, and necessary evaluation of new ones. *Parasite* 2014;21:74.
 38. Tao S, Qin Z, Hao W, Yongquan L, Lanhui Y, Lei Y. Usefulness of gray-scale contrast-enhanced ultrasonography (SonoVue(R)) in diagnosing hepatic alveolar echinococcosis. *Ultrasound Med Biol* 2011;37:1024-1028.
 39. Cai DM, Wang HY, Wang XL, Jiang Y, Luo Y, Li YZ. Ultrasonographic findings of small lesion of hepatic alveolar echinococcosis. *Acta Trop* 2017;174:165-170.
 40. Ehrhardt AR, Reuter S, Buck AK, et al. Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [(18)F] fluorodeoxyglucose positron emission tomography. *Abdom Imaging* 2007;32:730-736.
 41. Zhang H, Liu ZH, Zhu H, Han Y, Liu J, Deng LQ. Analysis of contrast-enhanced ultrasound (CEUS) and pathological images of hepatic alveolar echinococcosis (HAE) lesions. *Eur Rev Med Pharmacol Sci* 2016;20:1954-1960.
 42. Kratzer W, Reuter S, Hirschbuehl K, et al. Comparison of contrast-enhanced power Doppler ultrasound (Levovist) and computed tomography in alveolar echinococcosis. *Abdom Imaging* 2005;30:286-290.
 43. Cai D, Li Y, Jiang Y, Wang H, Wang X, Song B. The role of contrast-enhanced ultrasound in the diagnosis of hepatic alveolar echinococcosis. *Medicine (Baltimore)* 2019;98:e14325.
 44. Zeng H, Wang J, Xie W, Liu W, Wen H. Assessment of early hepatic echinococcus multilocularis infection in rats with real-time contrast-enhanced ultrasonography. *Ultrasound Med Biol* 2012;38:1982-1988.
 45. Bresson-Hadni S, Delabrousse E, Blagosklonov O, et al. Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. *Parasitol Int* 2006;55 Suppl:S267-272.
 46. Mas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. *Adv Parasitol* 2009;69:41-146.
 47. Ashrafi K, Bargues MD, O'Neill S, Mas-Coma S. Fascioliasis: a worldwide parasitic disease of importance in travel medicine. *Travel Med Infect Dis* 2014;12:636-649.
 48. Leerapun A, Puasripun S, Kijdamrongthum P, Thongsawat S. Human fascioliasis presenting as liver abscess: clinical characteristics and management. *Hepatol Int* 2021.
 49. Mueller J, Dagenbach S, Riecken B, Klingler C. [Ambiguous hepatic mass and fever after stay in Turkey]. *Internist (Berl)* 2017;58:503-506.
 50. Saijuntha W, Sithithaworn P, Kiatsopit N, Andrews RH, Petney TN. Liver Flukes: Clonorchis and Opisthorchis. *Adv Exp Med Biol* 2019;1154:139-180.
 51. Dietrich CF, Sharma M, Chaubal N, et al. Ascariasis imaging: pictorial essay. *Z Gastroenterol* 2017;55:479-489.
 52. Javid G, Wani NA, Gulzar GM, et al. Ascaris-induced liver abscess. *World J Surg* 1999;23:1191-1194.
 53. Khuroo MS, Rather AA, Khuroo NS, Khuroo MS. Hepatobiliary and pancreatic ascariasis. *World J Gastroenterol* 2016;22:7507-7517.
 54. Dong Y, Mao F, Cao J, et al. Differential diagnosis of gallbladder ascariasis debris: the added value of contrast enhanced ultrasound with high frequency transducer. *Med Ultrason* 2018;20:413-419.
 55. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. *Lancet* 2014;383:2253-2264.
 56. Burki A, Tanner M, Burnier E, Schweizer W, Meudt R, Degremont A. Comparison of ultrasonography, intravenous pyelography and cystoscopy in detection of urinary tract lesions due to *Schistosoma haematobium*. *Acta Trop* 1986;43:139-151.
 57. Dumurgier C, Tay KH, Surith TN, et al. [Place of surgery in the prevention of recurrences of digestive haemorrhages at the patients presenting a portal hypertension due to *Schistosoma mekongi*]. *Bull Soc Pathol Exot* 2006;99:365-371.
 58. Ohmae H, Tanaka M, Hayashi M, et al. Ultrasonographic and serologic abnormalities in *Schistosoma japonicum* infection in Leyte, the Philippines. *Am J Trop Med Hyg* 1992;46:89-98.
 59. Warren KS. The kinetics of hepatosplenic schistosomiasis. *Semin Liver Dis* 1984;4:293-300.
 60. Richter J, Domingues AL, Barata CH, Prata AR, Lambertucci JR. Report of the second satellite symposium on ultrasound in schistosomiasis. *Mem Inst Oswaldo Cruz* 2001;96 Suppl:151-156.
 61. el Scheich T, Holtfreter MC, Ekamp H, et al. The WHO ultrasonography protocol for assessing hepatic morbidity due to *Schistosoma mansoni*. Acceptance and evolution over 12 years. *Parasitol Res* 2014;113:3915-3925.
 62. Monzawa S, Uchiyama G, Ohtomo K, Araki T. Schistosomiasis japonica of the liver: contrast-enhanced CT findings in 113 patients. *AJR Am J Roentgenol* 1993;161:323-327.
 63. Richter J, Bode JG, Blondin D, et al. Severe liver fibrosis caused by *Schistosoma mansoni*: management and treat-

- ment with a transjugular intrahepatic portosystemic shunt. *Lancet Infect Dis* 2015;15:731-737.
64. Richter J, Azoulay D, Dong Y, et al. Ultrasonography of gallbladder abnormalities due to schistosomiasis. *Parasitol Res* 2016;115:2917-2924.
 65. Dietrich CF, Cretu C, Dong Y. Imaging of toxocariasis. *Adv Parasitol* 2020;109:165-187.
 66. Lim JH. Toxocariasis of the liver: visceral larva migrans. *Abdom Imaging* 2008;33:151-156.
 67. Sasaki M, Kamiyama T, Yano T, Nakamura-Uchiyama F, Nawa Y. Active hepatic capsulitis caused by *Paragonimus westermani* infection. *Intern Med* 2002;41:661-663.
 68. Lu Q, Ling WW, Ma L, Huang ZX, Lu CL, Luo Y. Contrast-enhanced ultrasonographic findings of hepatic paragonimiasis. *World J Gastroenterol* 2013;19:2087-2091.
 69. Lu CY, Hu YJ, Chen WX. Characteristic MR and CT imaging findings of hepatobiliary paragonimiasis and their pathologic correlations. *Acta Radiol* 2012;53:481-484.
 70. Gong Z, Xu Z, Lei C, Wan C. Hepatic paragonimiasis in a 15-month-old girl: a case report. *BMC Pediatr* 2017;17:190.
 71. Lin YX, Jia QB, Fu YY, Xiong XZ. Hepatic Paragonimiasis Mimicking Hepatocellular Carcinoma. *J Gastrointest Surg* 2018;22:550-552.
 72. Doehring E, Reider F, Dittrich M, Coddi Z. Ultrasonographic findings in the livers of patients with lepromatous leprosy. *J Clin Ultrasound* 1986;14:179-183.
 73. Taneja K, Khanna NV, Shiv VK, Pandhi RK, Bhargava SK. Hepatic ultrasonography in patients with lepromatous leprosy. *Indian J Lepr* 1990;62:443-447.
 74. Bonacini M, Kanel G, Alamy M. Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. *Am J Gastroenterol* 1996;91:1838-1840.
 75. Choi YI, Hwang S, Park GC, et al. Clinical outcomes of *Pneumocystis carinii* pneumonia in adult liver transplant recipients. *Transplant Proc* 2013;45:3057-3060.
 76. Iriart X, Bouar ML, Kamar N, Berry A. *Pneumocystis* Pneumonia in Solid-Organ Transplant Recipients. *J Fungi (Basel)* 2015;1:293-331.
 77. Organization. WH. Leishmaniasis. In: <https://www.who.int/news-room/fact-sheets/detail/leishmaniasis>; 2019.
 78. Belard S, Tamarozzi F, Bustinduy AL, et al. Point-of-Care Ultrasound Assessment of Tropical Infectious Diseases--A Review of Applications and Perspectives. *Am J Trop Med Hyg* 2016;94:8-21.
 79. Piccioni A, Valletta F, Zanza C, et al. Rapid Clinical Management of Leishmaniasis in Emergency Department: A Case Report with Clinical Review of Recent Literature. *Biology (Basel)* 2020;9:351.
 80. Mao G, Yang G, Cheng Y, et al. Multiple nodular lesions in spleen associated with visceral leishmaniasis: a case report of MRI-findings. *Medicine (Baltimore)* 2014;93:e272.
 81. Tatarelli P, Fornaro G, Del Bono V, et al. Visceral leishmaniasis in hematopoietic cell transplantation: Case report and review of the literature. *J Infect Chemother* 2018;24:990-994.
 82. Bobbio F, Di Gennaro F, Marotta C, et al. Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study. *BMJ Open* 2019;9:e027179.
 83. Wilhelm TJ. [Visceral leishmaniasis]. *Chirurg* 2019;90:833-837.
 84. Melchionda F, Varani S, Carfagnini F, et al. Spleen nodules: a potential hallmark of Visceral Leishmaniasis in young children. *BMC Infect Dis* 2014;14:620.
 85. Bi K, Chen Y, Zhao S, Kuang Y, John Wu CH. Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study. *Biomed Res Int* 2018;2018:9872095.
 86. Sihuyang D, Gornals JB, Saumoy M, et al. Visceral leishmaniasis with mediastinal lymphadenopathy diagnosed with endoscopic ultrasound-guided fine needle aspiration. *Rev Esp Enferm Dig* 2016;108:736-738.
 87. Artan R, Yilmaz A, Akcam M, Aksoy NH. Liver biopsy in the diagnosis of visceral leishmaniasis. *J Gastroenterol Hepatol* 2006;21:299-302.
 88. Martino G, Ascani S. Seronegative visceral leishmaniasis with bone marrow and hepatic involvement. *Blood* 2019;133:2353.
 89. Kumar B, Verma P. Role of fine-needle aspiration cytology in the prompt diagnosis of recurrence of visceral leishmaniasis presented as isolated cervical leishmanial lymphadenopathy. *Diagn Cytopathol* 2013;41:150-152.
 90. Kaye PM, Beattie L. Lessons from other diseases: granulomatous inflammation in leishmaniasis. *Semin Immunopathol* 2016;38:249-260.
 91. Gangneux JP, Donaghy L, Marty P. [Liver involvement during visceral leishmaniasis]. *Gastroenterol Clin Biol* 2006;30:1027-1032.
 92. Martinez de Narvajas I, Diaz A, Bassegoda O, et al. Acute liver failure due to visceral leishmaniasis in Barcelona: a case report. *BMC Infect Dis* 2019;19:874.
 93. Mueller YK, Kolaczinski JH, Koech T, et al. Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. *Am J Trop Med Hyg* 2014;90:33-39.
 94. Abdinia B, Oliaei-Motlagh M, Teimouri-Dereshki A. Pediatric visceral leishmaniasis in northwest of Iran. *Medicine (Baltimore)* 2016;95:e5261.
 95. Raeymaeckers S, Docx M, Demeyere N. MRI-findings of nodular lesions in an enlarged spleen, associated with visceral Leishmaniasis. *Eur J Radiol* 2012;81:2550-2553.
 96. Stojkovic M, Muller J, Junghans T, Weber TF. Radiological Diagnoses in the Context of Emigration: Infectious diseases. *Rofo* 2018;190:121-133.
 97. Bukte Y, Nazarovlu H, Mete A, Yilmaz F. Visceral leishmaniasis with multiple nodular lesions of the liver and spleen: CT and sonographic findings. *Abdom Imaging* 2004;29:82-84.
 98. Rinaldi F, Giache S, Spinicci M, et al. Focal spleen lesions in visceral leishmaniasis, a neglected manifestation of a neglected disease: report of three cases and systematic review of literature. *Infection* 2019;47:507-518.

99. Choudhary NS, Kataria S, Guleria M, Puri R. Leishmaniasis presenting as small isolated mediastinal lymphadenopathy diagnosed by endoscopic ultrasound-guided fine-needle aspiration. *Endoscopy* 2015;47 Suppl 1 UCTN:E147-148.
100. Tajebe F, Getahun M, Adem E, et al. Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites. *PLoS Negl Trop Dis* 2017;11:e0005727.
101. Mohammed R, Gebrewold Y, Schuster A, et al. Abdominal ultrasound in the diagnostic work-up of visceral leishmaniasis and for detection of complications of spleen aspiration. *PLoS Negl Trop Dis* 2021;15:e0009107.
102. Belard S, Stratta E, Zhao A, et al. Sonographic findings in visceral leishmaniasis - A narrative review. *Travel Med Infect Dis* 2021;39:101924.